Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study
![Thumbnail](/xmlui/themes/Mirage2//images/restricted.png)
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2017Yazar
Bilir, CemilYıldız, İbrahim
Bilici, Ahmet
Uçar, Mahmut
Berk, Veli
Yıldız, Yaşar
Yazıcı, Ozan
İnanç İmamoğlu, Gökşen
Karadurmuş, Nuri
Pilancı, Kezban Nur
Arpacı, Erkan
Tanrıverdi, Özgür
Karcı, Ebru
Temiz, Süleyman
Nayır, Erdinç
Oktay, Esin
Dal, Pınar
Petekkaya, İbrahim
Varım, Ceyhun
Cinemre, Hakan
Üst veri
Tüm öğe kaydını gösterKünye
Bilir, C., Yıldız, İ., Bilici, A., Uçar, M., Berk, V., Yıldız, Y. ... Cinemre, H. (2017). Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study. Cancer Investigation, 35(4), 248-255. https://dx.doi.org/10.1080/07357907.2017.1292518Özet
Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.
WoS Q Kategorisi
Q4Scopus Q Kategorisi
Q2Kaynak
Cancer InvestigationCilt
35Sayı
4Koleksiyonlar
- Makale Koleksiyonu [3790]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]